Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:16 PM
Ignite Modification Date:
2025-12-24 @ 11:16 PM
NCT ID:
NCT03800056
Eligibility Criteria:
Inclusion Criteria:
1. For both of groups, inclusion criteria are :
* children aged 0 to 17 years old with the consent of both parents, and men and women between the ages of 18 and 85.
* a reasonable delay of 2 weeks after the resolution of an intercurrent infectious episode is to be observed.
* assent of the patient after information adapted to his age and his degree of understanding.
* informed, express and written consent of the patient or of each of the holders of parental authority.
2. Inclusion criteria specific to group 1: Patients with a APS type 1 whose molecular diagnosis (mutation of the AIRE gene) has been established in the diagnosis of the disease, regardless of their mycological status (history of mycosis) or the presence of antifungal treatment.
3. Inclusion criteria specific to group 2 : Patients with APS type 2: - with adrenal insufficiency for 50% of them. - a delay of two weeks after stopping antifungal or antibiotic treatment in patients is to be respected.
Exclusion Criteria:
* impossibility to receive informed information for adults, or impossibility to receive enlightened information for the holders of parental authority if minor subject
* inability to participate in the entire study, refusal to sign the consent.
* people in an emergency situation.
* persons deprived of their liberty.
* pregnant or lactating woman (pregnant women will be offered to participate in the study after delivery).
Healthy Volunteers:
False
Sex:
ALL
Maximum Age:
85 Years
Study:
NCT03800056
Study Brief:
Protocol Section:
NCT03800056